Albumin treatment regimen for type 1 hepatorenal syndrome: a dose–response meta-analysis

BACKGROUND: Recommended treatment for type 1 hepatorenal syndrome consists of albumin and vasoconstrictor. The optimal albumin dose remains poorly characterized. This meta-analysis aimed to determine the impact of albumin dose on treatment outcomes. METHODS: Clinical studies of type 1 hepatorenal sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Salerno, Francesco, Navickis, Roberta J., Wilkes, Mahlon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660686/
https://www.ncbi.nlm.nih.gov/pubmed/26606982
http://dx.doi.org/10.1186/s12876-015-0389-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660686/
https://www.ncbi.nlm.nih.gov/pubmed/26606982
http://dx.doi.org/10.1186/s12876-015-0389-9

Ejemplares similares